Q3 2025 Boston Scientific Corp Earnings Call Transcript
Key Points
- Boston Scientific Corp (BSX) reported a 19% growth in total company operational sales and a 15% increase in organic sales, exceeding their guidance range.
- The company achieved a 19% growth in adjusted EPS, surpassing the high end of their guidance range.
- Strong performance in the Cardiovascular and MedSurg segments contributed to the company's success.
- The WATCHMAN device saw a 35% growth, with significant market penetration and future growth potential.
- The company is expanding its portfolio with the acquisition of Nalu Medical, enhancing its presence in the pain management market.
- The Europe, Middle East, and Africa (EMEA) region experienced a 2% decline in operational sales due to the discontinuation of the ACURATE valve and ERP system upgrades.
- The Axonics performance in the urology segment was below expectations, impacting overall growth.
- The Peripheral Interventions segment faced challenges in China due to the DBP, affecting sales growth.
- The company is dealing with a $30 million backorder issue in Europe due to ERP system implementation, impacting several business segments.
- The Cardiac Rhythm Management segment grew only 2%, with high-voltage business declining slightly.
Good morning and welcome to the Boston Scientific third-quarter 2025 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Lauren Tengler, Vice President-Investor Relations. Please go ahead.
Thank you, Drew, and thanks to everyone for joining us. With me today are Mike Mahoney, Chairman and Chief Executive Officer; and Jon Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and Jon will be joined by our Chief Medical Officer, Dr. Ken Stein.
We issued a press release earlier this morning announcing our Q3 results, which included reconciliations of the non-GAAP measures. The release as well as reconciliations of the non-GAAP measures used in today's call can be found on the Investor Relations section of our website.
Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations. And organic revenue further exclude
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
